Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed primarily against several immune checkpoint proteins, including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1) in the tumor microenvironment (TME). This evidence concerns the gene PDCD1 and neoplasm.